SCHEMBL329047

SCHEMBL329047

CC(=O)OC(=O)C(c1ccccc1)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.53
TDP1 Q9NUW8 2/20 0.52
CHRM1 P11229 6/20 0.51
CHRM3 P20309 6/20 0.51
CHRM2 P08172 5/20 0.51
CHRM4 P08173 5/20 0.51
ALDH1A1 P00352 4/20 0.50
CYP3A4 P08684 2/20 0.50
LMNA P02545 3/20 0.49
CYP1A2 P05177 2/20 0.49
CYP2D6 P10635 2/20 0.49
KMT2A Q03164 2/20 0.48
KLK7 P49862 3/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
CHRM5 P08912 2/20 0.46
THRB P10828 2/20 0.46
BLM P54132 2/20 0.46
PMP22 Q01453 2/20 0.46
MEN1 O00255 1/20 0.46
CYP2C9 P11712 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL329046 0.87 L3MBTL1 (0.60) L3MBTL1TDP1CHRM1CHRM3CHRM2
SCHEMBL28984887 0.83 L3MBTL1 (0.56) L3MBTL1TDP1CHRM1CHRM3CHRM2
SCHEMBL4202325 0.82 KMT2A (0.47) L3MBTL1ALDH1A1CYP3A4LMNACYP2D6
SCHEMBL378836 0.82 LMNA (0.54) TDP1CHRM1CHRM3CHRM2CHRM4
SCHEMBL2761810 0.82 LMNA (0.54) TDP1CHRM1CHRM3CHRM2CHRM4
SCHEMBL10527197 0.82 KMT2A (0.47) L3MBTL1ALDH1A1CYP3A4LMNACYP2D6
SCHEMBL1040186 0.82 LMNA (0.54) TDP1CHRM1CHRM3CHRM2CHRM4
SCHEMBL22880630 0.81 HPGD (0.49) L3MBTL1TDP1CHRM1CHRM3CHRM2
Hydrochloric Acid SCHEMBL5367883 0.80 LMNA (0.52) TDP1CHRM1CHRM3CHRM2CHRM4
SCHEMBL4642047 0.80 KMT2A (0.46) L3MBTL1CHRM1CHRM3CHRM2CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119978575-A Ageing-resistant emulsion and processing technology thereof 温州佳盛乳胶制品有限公司 2025-05-13 CN claimed
CN-113332496-A Preparation of composite scaffold material for vascular tissue engineering 杭州鹿扬科技有限公司 2021-09-03 CN claimed
EP-2407447-B1 METHOD FOR PRODUCING OPTICALLY ACTIVE 2-HYDROXY ESTER TOKYO UNIV OF SCIENCE EDUCATIONAL FOUNDATION ADMINISTRATIVE ORGANIZATION (JP) 2018-04-18 EP claimed
US-8552215-B2 Method for producing optically active 2-hydroxy ester and novel intermediate compound TOKYO UNIVERSITY OF SCIENCE EDUCATIONAL FOUNDATION ADMINISTRATIVE ORGANIZATION (JP) 2013-10-08 US claimed
EP-2407447-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE 2-HYDROXY ESTER AND NOVEL INTERMEDIATE COMPOUND Tokyo University Of Science Educational Foundation Administrative Organization (JP) 2012-01-18 EP claimed
US-20110319650-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE 2-HYDROXY ESTER AND NOVEL INTERMEDIATE COMPOUND TOKYO UNIVERSITY OF SCIENCE EDUCATIONAL FOUNDATION ADMINISTRATIVE ORGANIZATION (JP) 2011-12-29 US claimed
EP-4730479-A2 FLAME-RETARDANT NON-AQUEOUS ELECTROLYTIC SOLUTION AND SECONDARY BATTERY USING SAME Kyoto University (JP) 2026-04-22 EP disclosed
US-20250246685-A1 FLAME-RETARDANT NON-AQUEOUS ELECTROLYTIC SOLUTION AND SECONDARY BATTERY USING SAME KYOTO UNIVERSITY (JP) 2025-07-31 US disclosed
WO-2025120994-A1 SECONDARY BATTERY NON-AQUEOUS ELECTROLYTE AND SECONDARY BATTERY PROVIDED WITH SAME ステラケミファ株式会社 2025-06-12 WO disclosed
CN-119978575-A Ageing-resistant emulsion and processing technology thereof 温州佳盛乳胶制品有限公司 2025-05-13 CN disclosed
CN-119978575-A Ageing-resistant emulsion and processing technology thereof 温州佳盛乳胶制品有限公司 2025-05-13 CN disclosed
WO-2025095088-A1 NON-AQUEOUS ELECTROLYTE SOLUTION FOR SECONDARY BATTERY, AND SECONDARY BATTERY PROVIDED WITH SAID SOLUTION ステラケミファ株式会社 2025-05-08 WO disclosed
US-12191448-B2 Nonaqueous electrolyte solution for secondary battery, and secondary battery provided with said solution STELLA CHEMIFA CORPORATION (JP) 2025-01-07 US disclosed
US-5532266-A Acrylacetamides MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1996-07-02 US disclosed
US-5196478-A Polystyrene, assays EPIPHARM ALLERGIE-SERVICE GESELLSCHAFT M.B.H. (AT) 1993-03-23 US disclosed
EP-0439585-A1 IMMOBILISATION OF LIGANDS BY RADIO-DERIVATIZED POLYMERS. EPIPHARM ALLERGIE SERVICE (AT) 1991-08-07 EP disclosed
WO-1991002768-A1 IMMOBILISATION OF LIGANDS BY RADIO-DERIVATIZED POLYMERS EPIPHARM ALLERGIE-SERVICE GESELLSCHAFT M.B.H. (AT) 1991-03-07 WO disclosed
US-4686229-A THROMBOEMBOLIC AND ISCHAEMIC DISORDERS BAYER AKTIENGESELLSCHAFT (DE) 1987-08-11 US disclosed
US-4139717-A 1,3-Dicarbonyl compounds TEIJIN LIMITED (JP) 1979-02-13 US disclosed
US-4009196-A HYPOTENSIVE AGENTS, BRONCHODILATORS, PROSTAGLANDIN ANALOGS TEIJIN LIMITED (JA) 1977-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319650-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE 2-HYDROXY ESTER AND NOVEL INTERMEDIATE COMPOUND CA7, HAO2, HACL2 L3MBTL1 2785/4885TDP1 4097/4885CHRM1 948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.